8-K
filed September 19, 2023, 7:59 PM ET
ticker CNSP
CIK 0001729427
other material
confidence high
sentiment neutral
materiality 0.15
CNS Pharma shareholders approve director slate, auditor, and 2020 equity plan amendment
CNS Pharmaceuticals, Inc.
- All 7 director nominees elected with majority votes; broker non-votes of 1.4M shares.
- Ratified MaloneBailey LLP as independent auditor for FY2023 (1.7M for, 40k against).
- Approved amendment to 2020 Equity Plan, increasing shares by 745,800 to total 845,800.
- Equity plan amendment also modified annual award limits per Participant.
- Director election and equity plan amendments each had 1.4M broker non-votes.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
CNS Pharmaceuticals, Inc. shareholders approved To approve amendments to the Company’s 2020 Stock Plan including an increase in the number of shares of common stock authorized for issuance under the 2020 Plan at the 2023-09-14 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-09-14
Exact text from the filing
Proposal 3. To approve amendments to the Company’s 2020 Stock Plan (the “2020 Plan”) including an increase in the number of shares of common stock authorized for issuance under the 2020 Plan – The Company’s stockholders approved an amendment to the 2020 Plan to increase the number of shares of common stock authorized for issuance under the 2020 Plan by 745,800 shares and to modify the maximum annual limits on awards issuable under the 2020 Plan, by the following vote:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
CNS Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-09-14 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-09-14
Exact text from the filing
Proposal 1. Election of Directors - The Company’s stockholders elected John Climaco, Jerzy (George) Gumulka, Jeffry R. Keyes, Andrzej Andraczke, Carl Evans, Faith Charles and Bettina Cockroft to serve until the 2024 Annual Meeting of Stockholders, or until their successors are duly elected and qualified, by the following vote.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
CNS Pharmaceuticals, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-09-14 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-09-14
Exact text from the filing
Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm - The Company's stockholders ratified the appointment of MaloneBailey, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, by the following vote:
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.